Patient characteristics for thalidomide phase 2 trial for advanced and refractory myeloma
Parameter . | % . |
|---|---|
| Age greater than 60 y | 44 |
| B2M greater than 6 mg/L | 22 |
| Abnormal cytogenetics | 67 |
| Deletion 13 | 37 |
| Prior therapy longer than 60 mo | 20 |
| Prior high-dose therapy | 76 |
| More than 1 cycle | 53 |
Parameter . | % . |
|---|---|
| Age greater than 60 y | 44 |
| B2M greater than 6 mg/L | 22 |
| Abnormal cytogenetics | 67 |
| Deletion 13 | 37 |
| Prior therapy longer than 60 mo | 20 |
| Prior high-dose therapy | 76 |
| More than 1 cycle | 53 |